Check City Honors Krrisha Patel With 2025 Richard Rawle Scholarship for Community-Driven Health Innovation
Krrisha, an aspiring bioengineer, has spent the last several years addressing body image, healthcare inequality, mental health, and inclusive innovation in bioengineering and telehealth.
Her journey began with Harvard's STRIPED Initiative, where she helped combat the dangers of diet pills and promote body positivity, contributing to legislation that prohibits their sale to minors. Motivated by peers facing eating disorders, she founded MetaHealth, a community group that offers nutrition workshops promoting healthy habits and self-image through inclusive dialogue and cuisine.
At the Institute for Healing & Justice in Medicine, Krrisha researched how racial and gender identities influence medical diagnoses and treatments. She also supported public health initiatives in Nigeria, addressing diseases like typhoid fever, and interned at IPMD Inc., helping develop an emotional AI telemedicine platform. Now, she's exploring wearable sensors and inclusive design to expand equitable care access.
The Richard Rawle Memorial Scholarship honors Check City's founder, whose life was defined by a commitment to lifting others. 'Krrisha embodies the spirit of this scholarship,' said the selection committee. 'Her community service efforts go beyond volunteerism—they reflect an ongoing, self-motivated commitment to making a broad impact on the world by lifting others and reshaping systems to be more inclusive and just.'
As the 2025 recipient, Krrisha will receive scholarship funds for her academic journey. She plans to continue studying bioengineering and lead the next generation of health innovations, prioritizing diversity, equity, and upfront accessibility.
The Rawle family and Check City firmly believe education plays a crucial role in community prosperity. This award gives deserving students the financial support to continue making a difference in their communities. Krrisha's work is a powerful reminder that service isn't just about giving back but moving forward together.
About Check City
Check City is a trusted financial services provider with locations across the United States. Founded on principles of community service and financial empowerment, Check City offers services like short-term lending, money transfers, and beyond. Learn more at checkcity.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
CWCI Examines California's Proposed Presumption for Hospital Worker Injuries & Illnesses
BUSINESS WIRE)--A bill that would give a rebuttable presumption of compensability to a wide range of work injury and illness claims filed by workers who provide direct patient care in California's acute care hospitals would require the hospitals to accept injuries that would normally be denied after investigation and expend significant costs, increase litigation, and set an unsupported precedent by extending presumptions into the private sector according to a California Workers' Compensation Institute (CWCI) analysis. The analysis shows a lack of evidence supporting the need for hospital worker presumptions, especially given that it would open the door to private sector presumptions. Share Unlike other workers' compensation claims, in presumptive injury claims an injured worker does not need to prove that their injury or illness was caused by their job; instead, the employer must prove it was not work-related. Because this is very difficult, rebuttable presumptions have historically been reserved for public safety officers for injuries such as cancer or heart disease that may arise from the unique risks inherent in those public sector jobs, and even then, only when there is clear and compelling evidence of a lack of hazard abatement, a high incidence of injury, and a high claim denial rate. However, SB 632 (Arreguin), now pending in the California Assembly, would extend presumptions into the private sector by granting presumptions to direct care hospital workers for claims involving injuries and illnesses including musculoskeletal injuries, COVID-19 from SARS-CoV-2 and its variants, respiratory diseases (including asthma), cancer, and post-traumatic stress disorder (PTSD). Using accident year (AY) 2019 – 2024 claims data from its Industry Research Information System (IRIS) database, CWCI's analysis measured the percentage of workers' compensation claims by hospital workers that involved the injuries covered by SB 632 and compared that figure to the percentage of claims from the general workforce that involved those injuries. The Institute then determined the distribution of claims by injury category and calculated the claim denial rates for the hospital worker claims and compared the results to those for the general workforce. Among the findings: 1) 55.7% of all hospital worker claims from AY 2019 - 2024 would be presumptive injuries under SB 632. 2) Of the hospital worker claims, the most common were musculoskeletal injuries (32.1% of all hospital worker claims from the 6-year study period); COVID-19 (21.7%); and respiratory diseases (1.3%). Other injury categories that would be covered by the proposed presumptions together represented less than 1% of the hospital worker claims. 3) Similarly, for the general workforce, the most common injuries covered by SB 632 were musculoskeletal injuries (30.0%), COVID-19 (9.9%), and respiratory diseases (0.8%). As with the hospital worker claims, all other injuries covered by SB 632 represented less than 1% of all general workforce claims. 4) Claim denial rates for injuries and illnesses that would be covered by SB 632 are similar for hospital workers and the general workforce: for hospital workers the claim denial rate was 15.0%; for the general workforce, it was 15.7%. Thus, hospitals accept liability for the injuries at a slightly higher rate than they are accepted in the general workforce. Workers' compensation presumptions shift the burden of proving that a claim is work-related from the employee to the employer. Because they create exceptions to the grand bargain of workers' compensation, they have been limited to public safety officers for specific injuries that may result from the hazardous conditions associated with those public service jobs, where it is often difficult to safeguard the employee from the dangerous conditions inherent in their work. Such is not the case for hospitals, which have extensive loss control programs and safety procedures. Furthermore, CWCI's analysis found hospitals and the general workforce have similar injury distributions, except for COVID-19 claims, where hospital workers were covered by a presumption during the pandemic. This, combined with nearly identical claim denial rates for hospital worker and general workforce claims involving injuries covered by SB 632, shows a lack of evidence supporting the need for a presumption, especially given that it would open the door to private sector presumptions. CWCI's Impact Analysis report on SB 632 is available for free under the Research tab at
Business Wire
an hour ago
- Business Wire
Mark Farrah Associates Reported Individual and Small Group Health Insurance Segment Profitability
MCMURRAY, Pa.--(BUSINESS WIRE)--Mark Farrah Associates (MFA), examined trends in membership, claims incurred PMPM (per member per month), adjusted premiums PMPM, and MLRs (Medical Loss Ratios) for the Individual and Small Group comprehensive medical/health insurance markets and segment leaders. Based on an analysis of the National Association of Insurance Commissioners (NAIC) Supplemental Health Care Exhibit (SHCE), MFA also analyzed the profitability of both health insurance segments for the last five years. The Individual and Small Group business segments were profitable for insurers in 2024 where both experienced higher MLRs between 2023 and 2024. The Individual segment experienced enrollment growth of 21%, to 21.5 million members for 2024. Premiums PMPM increased 1.8%, to a segment average of $559 PMPM. The average medical claims PMPM of $493 in 2024 was an increase of 2.3% from 2023. The Small Group segment continues to lose membership, down another 7% to 7.9 million in 2024. Average claims incurred PMPM increased from $495 in 2023 to $537 in 2024, an 8.4% increase. To read the full text of " An Analysis of Profitability for the Individual and Small Group Health Insurance Markets in 2024 ' visit the MFA Briefs library on Mark Farrah Associates' website. MFA will continue to monitor health plan performance and competitive shifts across all healthcare segments. About Mark Farrah Associates (MFA) MFA is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. Committed to simplifying analysis of health insurance business, our products include: Health Coverage Portal™, Medicare Business Online™, Medicare Benefits Analyzer™, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus. Follow us on LinkedIn!
Business Wire
an hour ago
- Business Wire
Seek Labs' BioSeeker ™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the Respiratory Syncytial Virus (RSV) genome using its proprietary BioSeeker™ discovery engine to address one of global health's most persistent and costly viral threats. By pinpointing highly conserved genomic targets, this mapping accelerates development of a programmable CRISPR-based therapeutic on the company's Programmable Target Ablation Platform (PTAP™). To date, only one antiviral drug has been approved to treat active RSV infection—used sparingly due to cost and significant adverse side effects—highlighting an urgent need for safe, scalable treatments. Seek Labs' approach enables development of a single pan-RSV therapeutic candidate designed to treat both A and B subtypes. RSV now joins a growing roster of mapped, high-priority viruses in Seek Labs' Global Disease Atlas, a continuously updated resource that is on track to map over 95% of the world's most consequential viral pathogens. Share RSV: An Urgent Global Health Threat Each year, RSV causes an estimated 30 million infections globally and more than 100,000 deaths, placing a heavy, recurring burden on healthcare systems worldwide. Seasonal surges routinely overwhelm pediatric wards and intensive care units in North America, Europe, and Australia, among others. Seek Labs' PTAP platform offers a fundamentally new approach to address this critical therapeutic gap, transforming the fight against RSV from limited treatment options to precise genomic targeting. BioSeeker Pinpoints RSV's Genomic Vulnerabilities BioSeeker scanned over 290,000 publicly available RSV sequences, identifying a multiplexed set of high-potential, PTAP-compatible genomic targets in stable and conserved regions critical for RSV viral replication. These sites form a blueprint for a programmable, CRISPR-based 'seek-and-destroy' therapeutic designed to precisely target RSV at its genetic core. This approach accelerates RSV therapeutic development and demonstrates the platform's potential to rapidly address other high-priority viral threats. Strategic Addition to the Global Disease Atlas RSV now joins a growing roster of mapped, high-priority viruses in Seek Labs' Global Disease Atlas, a continuously updated resource that is on track to map over 95% of the world's most consequential viral pathogens. By building this strategic repository of high-impact targets, Seek Labs is equipping partners with tools to respond quickly and decisively to both endemic challenges like RSV and future emerging threats. Call for Development Partners Seek Labs is actively advancing development of an RSV-targeted therapeutic and invites qualified partners to join this vital effort. By combining BioSeeker's precision target maps with the company's cutting-edge Programmable Target Ablation Platform, Seek Labs offers partners an accelerated, de-risked path to advance a potential breakthrough RSV therapeutic and establish leadership in the next generation of programmable antivirals. About Seek Labs At Seek Labs, we don't wait for change—we build it. We're seeking the breakthroughs the world can't wait for by developing programmable 'seek and destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker™, these platforms form a full-stack development engine—from target discovery to real-world deployment—designed to accelerate innovation and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.
